Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACOG NASDAQ:AQST NASDAQ:AURA NASDAQ:FDMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACOGAlpha Cognition$6.10+0.2%$6.08$4.50▼$11.54$132.60M2.3841,715 shs11,741 shsAQSTAquestive Therapeutics$4.32+2.1%$4.14$2.12▼$7.55$525.72M1.51.19 million shs1.89 million shsAURAAura Biosciences$8.40+2.4%$6.66$4.34▼$9.53$526.44M0.37679,491 shs1.05 million shsFDMT4D Molecular Therapeutics$10.14+2.1%$9.38$3.00▼$12.34$519.09M2.77698,501 shs832,043 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACOGAlpha Cognition0.00%+2.01%-8.28%+19.41%-18.69%AQSTAquestive Therapeutics0.00%+3.17%+1.20%+2.92%+55.23%AURAAura Biosciences0.00%+16.31%+21.12%+46.43%+65.92%FDMT4D Molecular Therapeutics0.00%+11.95%-1.68%+10.46%+218.27%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACOGAlpha Cognition$6.10+0.2%$6.08$4.50▼$11.54$132.60M2.3841,715 shs11,741 shsAQSTAquestive Therapeutics$4.32+2.1%$4.14$2.12▼$7.55$525.72M1.51.19 million shs1.89 million shsAURAAura Biosciences$8.40+2.4%$6.66$4.34▼$9.53$526.44M0.37679,491 shs1.05 million shsFDMT4D Molecular Therapeutics$10.14+2.1%$9.38$3.00▼$12.34$519.09M2.77698,501 shs832,043 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACOGAlpha Cognition0.00%+2.01%-8.28%+19.41%-18.69%AQSTAquestive Therapeutics0.00%+3.17%+1.20%+2.92%+55.23%AURAAura Biosciences0.00%+16.31%+21.12%+46.43%+65.92%FDMT4D Molecular Therapeutics0.00%+11.95%-1.68%+10.46%+218.27%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACOGAlpha Cognition 3.00Buy$16.00162.30% UpsideAQSTAquestive Therapeutics 3.00Buy$8.80103.70% UpsideAURAAura Biosciences 2.40Hold$21.50155.95% UpsideFDMT4D Molecular Therapeutics 2.67Moderate Buy$29.88194.63% UpsideCurrent Analyst Ratings BreakdownLatest ACOG, FDMT, AURA, and AQST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026FDMT4D Molecular Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$33.004/29/2026AURAAura Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$22.00 ➝ $24.004/27/2026ACOGAlpha Cognition HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.004/24/2026AQSTAquestive Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$8.004/20/2026AQSTAquestive Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026FDMT4D Molecular Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/17/2026ACOGAlpha Cognition Craig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$14.003/30/2026AURAAura Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$22.003/30/2026FDMT4D Molecular Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.00 ➝ $21.003/27/2026AURAAura Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/20/2026FDMT4D Molecular Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$36.00(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACOGAlpha Cognition$10.22M12.99N/AN/A$2.88 per share2.12AQSTAquestive Therapeutics$44.54M12.06N/AN/A($0.28) per share-15.43AURAAura BiosciencesN/AN/AN/AN/A$2.16 per shareN/AFDMT4D Molecular Therapeutics$85.21M6.22N/AN/A$8.85 per share1.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACOGAlpha Cognition-$20.67M-$1.16N/AN/AN/A-202.23%-55.71%-43.78%5/14/2026 (Confirmed)AQSTAquestive Therapeutics-$83.78M-$0.78N/AN/AN/A-188.09%N/A-64.46%5/13/2026 (Estimated)AURAAura Biosciences-$106.19M-$1.79N/AN/AN/AN/A-71.25%-59.06%5/21/2026 (Estimated)FDMT4D Molecular Therapeutics-$140.11M-$2.57N/AN/AN/A-182.34%-37.26%-32.96%N/ALatest ACOG, FDMT, AURA, and AQST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026AURAAura Biosciences-$0.40N/AN/AN/AN/AN/A5/14/2026Q1 2026ACOGAlpha Cognition-$0.41N/AN/AN/A$3.42 millionN/A5/13/2026Q1 2026AQSTAquestive Therapeutics-$0.14N/AN/AN/A$10.90 millionN/A5/7/2026Q1 2026FDMT4D Molecular Therapeutics-$0.97-$1.01-$0.04-$1.01$2.59 million$3.05 million3/30/2026Q4 2025AURAAura Biosciences-$0.43-$0.37+$0.06-$0.37N/AN/A3/26/2026Q4 2025ACOGAlpha Cognition-$0.27-$0.30-$0.03-$0.30$4.41 million$2.60 million3/18/2026Q4 2025FDMT4D Molecular Therapeutics-$0.53$0.43+$0.96$0.43$30.86 million$85.09 million3/4/2026Q4 2025AQSTAquestive Therapeutics-$0.13-$0.26-$0.13-$0.26$13.28 million$13.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACOGAlpha CognitionN/AN/AN/AN/AN/AAQSTAquestive TherapeuticsN/AN/AN/AN/AN/AAURAAura BiosciencesN/AN/AN/AN/AN/AFDMT4D Molecular TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACOGAlpha CognitionN/A8.658.09AQSTAquestive TherapeuticsN/A3.143.01AURAAura BiosciencesN/A8.158.15FDMT4D Molecular TherapeuticsN/A9.399.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACOGAlpha CognitionN/AAQSTAquestive Therapeutics32.45%AURAAura Biosciences96.75%FDMT4D Molecular Therapeutics99.27%Insider OwnershipCompanyInsider OwnershipACOGAlpha Cognition14.00%AQSTAquestive Therapeutics6.81%AURAAura Biosciences6.30%FDMT4D Molecular Therapeutics9.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACOGAlpha CognitionN/A21.77 million18.73 millionN/AAQSTAquestive Therapeutics160124.29 million115.82 millionOptionableAURAAura Biosciences5064.20 million60.16 millionNot OptionableFDMT4D Molecular Therapeutics12052.28 million47.26 millionOptionableACOG, FDMT, AURA, and AQST HeadlinesRecent News About These Companies4D Molecular Therapeutics (NASDAQ:FDMT) Cut to Sell at Wall Street ZenMay 9 at 2:57 AM | americanbankingnews.com4D Molecular Therapeutics (NASDAQ:FDMT) Lowered to "Sell" Rating by Wall Street ZenMay 9 at 2:56 AM | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Down After Earnings MissMay 8 at 10:10 AM | marketbeat.com4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue EstimatesMay 7 at 8:11 PM | zacks.com4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming MilestonesMay 7 at 4:05 PM | globenewswire.com4DMT to Participate in Upcoming Investor ConferencesMay 4, 2026 | globenewswire.com4D Molecular Therapeutics (FDMT) to Release Quarterly Earnings on ThursdayApril 30, 2026 | marketbeat.com4D Molecular Therapeutics, Inc.April 27, 2026 | edition.cnn.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Recommendation of "Moderate Buy" from AnalystsApril 21, 2026 | marketbeat.com4DMT Announces New Employment Inducement GrantsApril 17, 2026 | globenewswire.comChardan Capital Remains a Buy on 4D Molecular Therapeutics (FDMT)March 21, 2026 | theglobeandmail.com4D Molecular Therapeutics (FDMT) Receives a Hold from Cantor FitzgeraldMarch 20, 2026 | theglobeandmail.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: 4D Molecular Therapeutics (FDMT), Protagonist Therapeutics (PTGX) and Trevi Therapeutics (TRVI)March 20, 2026 | theglobeandmail.comReimbursement and Pricing Pressures Threaten Commercial Outlook for 4D Molecular Therapeutics’ Gene TherapiesMarch 20, 2026 | tipranks.com4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat EstimatesMarch 18, 2026 | zacks.com4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming MilestonesMarch 18, 2026 | globenewswire.com4DMT to Participate in Upcoming Investor MeetingsMarch 16, 2026 | globenewswire.com4D Molecular Therapeutics, Inc. (FDMT) Presents at Barclays 28th Annual Global Healthcare Conference TranscriptMarch 12, 2026 | seekingalpha.com4D Molecular Therapeutics, Inc. (FDMT) Presents at TD Cowen 46th Annual Health Care Conference Prepared Remarks TranscriptMarch 6, 2026 | seekingalpha.comWhere is 4D Molecular Therapeutics (FDMT) Headed According to the Street?February 28, 2026 | insidermonkey.com4DMT to Participate in Upcoming Investor ConferencesFebruary 19, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026Does Cheesecake Factory Stock Have Any Upside Left on the Menu?By Jennifer Ryan Woods | April 27, 2026Chipotle Stock Just Hit Bottom—Is a Breakout Next?By Thomas Hughes | April 30, 2026Toast Finally Cracks Profit—But a Bigger Risk LoomsBy Peter Frank | April 23, 2026ACOG, FDMT, AURA, and AQST Company DescriptionsAlpha Cognition NASDAQ:ACOG$6.10 +0.01 (+0.16%) Closing price 05/8/2026 03:59 PM EasternExtended Trading$6.16 +0.06 (+0.90%) As of 05/8/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.Aquestive Therapeutics NASDAQ:AQST$4.32 +0.09 (+2.13%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$4.30 -0.03 (-0.58%) As of 05/8/2026 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.Aura Biosciences NASDAQ:AURA$8.40 +0.20 (+2.44%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$8.39 -0.01 (-0.12%) As of 05/8/2026 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.4D Molecular Therapeutics NASDAQ:FDMT$10.14 +0.21 (+2.11%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$10.24 +0.10 (+0.99%) As of 05/8/2026 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/04 - 05/08 SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
